> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Nuvectis Gets Orphan Status for NXP800
- URL: https://www.fdaweb.com/nuvectis-gets-orphan-status-for-nxp800/
- Published: 2024-08-29T12:00:00.000Z
- Updated: 2026-09-14T14:39:54.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157683

FDA has granted Nuvectis Pharma an orphan drug designation for NXP800 and its use in treating AT-rich interactive domain-containing protein 1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. NXP800 is described as an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for treating platinum-resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for treating cholangiocarcinoma, according to the company. Data from the trial are expected to be presented this fall, it adds.